Perioperative treatment and biomarker analysis of LP002, an anti‐PD‐L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer

Abstract

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review

“…Among the 33 included studies, there were seven randomized controlled trials (RCTs) ( 31 , 35 , 39 , 40 , 54 , 56 , 58 ) and 26 single-arm open-label cohort studies ( 27 , 28 , 30 , 32 – 34 , 36 – 38 , 41 – 53 , 55 , 57 , 59 , 60 ). The main neoadjuvant immunotherapy drugs used were avelumab, camrelizumab, pembrolizumab, sintilimab, tislelizumab, nivolumab, LP002, and durvalumab.…”

“…A sensitivity analysis was performed by removing the included studies in order, with the aim to confirm that the conjunction results were not significantly impacted by an individual trial. Of the 33 studies analyzing individual studies of PCR incidence, the two studies by Hirotaka Hasegawa ( 47 ) and Jia-lin Tang ( 41 ) contributed the most to the heterogeneity, although the weights given in these two studies were not the greatest. Heterogeneity was significantly reduced after excluding the two studies (P = 0.02; I 2 = 39%), and the remaining 31 combined trials still significantly demonstrated the safety of neoadjuvant immunotherapy in combination with chemotherapy (OR = 25%; 95% CI: 22%–27; p < 0.0001; Supplementary Figure 3 ).…”